Detalles de la búsqueda
1.
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
EBioMedicine
; 73: 103630, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34688030
Resultados
1 -
1
de 1
1
Próxima >
>>